The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...
Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the … ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...
Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.
HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW. Results for the ...
The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...
Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...
The finance round was led by OrbiMed and comes almost exactly two years after Mereo decided to pull a US IPO, blaming challenging market conditions. In the phase 1b combination study, a total of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback